Human GLP-2(Glucagon Like Peptide 2) ELISA Kit (E-EL-H2238)

This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Human GLP-2. During the reaction, Human GLP-2 in the sample or standard competes with a fixed amount of Human GLP-2 on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Human GLP-2. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Human GLP-2 in tested samples can be calculated by comparing the OD of the samples to the standard curve.

Glucagon-like peptide 2 (GLP-2) is a 33-amino-acid intestinotrophic hormone generated by tissue-specific processing of proglucagon, the same precursor that yields glucagon, GLP-1, glicentin and oxyntomodulin. It is produced and secreted mainly by enteroendocrine L cells of the distal ileum and colon in response to nutrient ingestion and to intestinal luminal signals, is rapidly inactivated by dipeptidyl peptidase-4 through cleavage at its N-terminal alanine, and circulates in a pattern closely linked to meal intake. GLP-2 acts through the GLP-2 receptor, a class B G protein-coupled receptor expressed on intestinal subepithelial myofibroblasts and enteric neurons, whose activation triggers the release of intermediaries including insulin-like growth factor 1, keratinocyte growth factor and transforming growth factor beta. Through this indirect route GLP-2 stimulates crypt cell proliferation, inhibits enterocyte apoptosis, enhances nutrient, fluid and electrolyte absorption, increases intestinal blood flow, reduces gastric motility and secretion and maintains tight-junction integrity, thereby enlarging the absorptive surface and strengthening the mucosal barrier. GLP-2 analogs such as teduglutide and glepaglutide are approved or under development for short bowel syndrome, where they promote adaptive hyperplasia of the remaining intestine and reduce parenteral support requirements. Measurement of GLP-2 supports research on intestinal adaptation, nutrient absorption, barrier repair, intestinal failure and mucosal injury, and the intestinotrophic action of the hormone makes it a focus of therapeutic development in inflammatory bowel disease and chemotherapy-induced enteropathy.